Vertex Pharmaceuticals Incorporated
VRTXNASDAQHealthcare● Active
$446.83
+$5.09(+1.15%)
Market Cap$113.4B
P/E Ratio—
52W High$507.92
52W Low$362.5
Vertex Pharmaceuticals Incorporated (VRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VRTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
$4.47
Est. $4.24 · +5.4%
Revenue
$2.99B
Est. $2.99B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
VRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $4.72 | — | — | — | $3.21B | — |
| ▲ Q2 FY2026 | May 4, 2026 | $4.24 | $4.47 | +5.4% | $2.99B | $2.99B | -0.2% |
| ▼ Q1 FY2026 | Feb 12, 2026 | $5.11 | $5.03 | -1.6% | $3.19B | $3.18B | +0.2% |
| ▲ Q4 FY2025 | Nov 3, 2025 | $4.57 | $4.80 | +5.0% | $3.08B | $3.06B | +0.6% |
| ▲ Q3 FY2025 | Aug 4, 2025 | $4.29 | $4.52 | +5.4% | $2.96B | $2.91B | +2.0% |
| ▼ Q2 FY2025 | May 5, 2025 | $4.25 | $4.06 | -4.5% | $2.77B | $2.86B | -3.2% |
| — Q1 FY2025 | Feb 10, 2025 | $4.02 | $3.98 | -1.0% | $2.91B | $2.78B | +4.6% |
| ▲ Q4 FY2024 | Nov 4, 2024 | $4.14 | $4.38 | +5.8% | $2.77B | $2.69B | +3.2% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$4.72
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
$4.47
EPS Est.
$4.24
EPS Surpr.
+5.4%
Revenue
$2.99B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
$5.03
EPS Est.
$5.11
EPS Surpr.
-1.6%
Revenue
$3.19B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$4.80
EPS Est.
$4.57
EPS Surpr.
+5.0%
Revenue
$3.08B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$4.52
EPS Est.
$4.29
EPS Surpr.
+5.4%
Revenue
$2.96B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$4.06
EPS Est.
$4.25
EPS Surpr.
-4.5%
Revenue
$2.77B
Q1 FY2025
Feb 10, 2025
EPS Actual
$3.98
EPS Est.
$4.02
EPS Surpr.
-1.0%
Revenue
$2.91B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$4.38
EPS Est.
$4.14
EPS Surpr.
+5.8%
Revenue
$2.77B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 7 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 7 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 7 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 7 |
| Q4 FY2027 | $5.85 | $6.03 | $6.19 | 6 |
| Q3 FY2027 | $5.50 | $5.66 | $5.81 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.9B | $3.9B | $4.0B | 9 |
| Q3 FY2028 | $3.7B | $3.8B | $3.8B | 14 |
| Q2 FY2028 | $3.6B | $3.6B | $3.7B | 7 |
| Q1 FY2028 | $3.5B | $3.5B | $3.6B | 10 |
| Q4 FY2027 | $3.7B | $3.8B | $3.8B | 8 |
| Q3 FY2027 | $3.6B | $3.6B | $3.7B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +5.4% | $423.92 | $429.85 | +1.40% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -1.6% | $461.24 | $465.02 | +0.82% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +5.0% | $425.57 | $426.00 | +0.10% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +5.4% | $462.13 | $472.27 | +2.19% |
| ▼ Q2 FY2025 | May 5, 2025 | -4.5% | $501.15 | $500.19 | -0.19% |
| ▲ Q1 FY2025 | Feb 10, 2025 | -1.0% | $469.32 | $469.97 | +0.14% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +5.8% | $471.12 | $472.80 | +0.36% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -10.3% | $495.72 | $505.78 | +2.03% |
Q2 FY2026+1.40%
Report Date
May 4, 2026
EPS Beat/Miss
+5.4%
Price Before
$423.92
Price After
$429.85
Q1 FY2026+0.82%
Report Date
Feb 12, 2026
EPS Beat/Miss
-1.6%
Price Before
$461.24
Price After
$465.02
Q4 FY2025+0.10%
Report Date
Nov 3, 2025
EPS Beat/Miss
+5.0%
Price Before
$425.57
Price After
$426.00
Q3 FY2025+2.19%
Report Date
Aug 4, 2025
EPS Beat/Miss
+5.4%
Price Before
$462.13
Price After
$472.27
Q2 FY2025-0.19%
Report Date
May 5, 2025
EPS Beat/Miss
-4.5%
Price Before
$501.15
Price After
$500.19
Q1 FY2025+0.14%
Report Date
Feb 10, 2025
EPS Beat/Miss
-1.0%
Price Before
$469.32
Price After
$469.97
Q4 FY2024+0.36%
Report Date
Nov 4, 2024
EPS Beat/Miss
+5.8%
Price Before
$471.12
Price After
$472.80
Q3 FY2024+2.03%
Report Date
Aug 1, 2024
EPS Beat/Miss
-10.3%
Price Before
$495.72
Price After
$505.78
Avg Beat Reaction+0.84%
Avg Miss Reaction+0.89%
Beat Rate5 / 8 quarters
Largest Move+2.19% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VRTX ends December
Vertex Pharmaceuticals Incorporated (VRTX) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $4.47 — beating the analyst consensus of $4.24 by +5.4%. The next VRTX earnings date is expected around September 1, 2026.
Each quarter, investors track VRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VRTX earnings · 5 questionsVertex Pharmaceuticals Incorporated's next earnings report is expected around September 1, 2026. VRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VRTX historically reports after market close (AMC).
VRTX earnings datewhen is VRTX earningsVRTX next earnings datewhen does VRTX report earningsVRTX earnings calendar
▸ Source: FMP · Vertex Pharmaceuticals Incorporated SEC filings · US GAAP · Vertex Pharmaceuticals Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026